mRNA levels of ESR1 and HER2 as predictive and prognostic markers of breast cancer

被引：0

作者：

Park, In Hae ^{[1
]}

Ro, Jungsil ^{[1
]}

机构：

[1] Natl Canc Ctr, Ctr Breast Canc, Kashiwa, Chiba, Japan

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 11期

关键词：

BEVACIZUMAB; EXPRESSION; THERAPY;

D O I：

10.2217/pgs.13.101

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1251 / 1253

页数：3

共 50 条

[21] Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer? [J].

Pritchard, Kathleen I. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) :3875-3876

[22] HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 [J].

Battaglin, Francesca ;

Ou, Fang-Shu ;

Qu, Xueping ;

Hochster, Howard S. ;

Niedzwiecki, Donna ;

Goldberg, Richard M. ;

Mayer, Robert J. ;

Ashouri, Karam ;

Zemla, Tyler J. ;

Blanke, Charles D. ;

Venook, Alan P. ;

Kabbarah, Omar ;

Lenz, Heinz-Josef ;

Innocenti, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16) :1890-1902

[23] HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer [J].

Kwon, Chae Hwa ;

Seo, Hyung Il ;

Kim, Dong Uk ;

Han, Sung Yong ;

Kim, Suk ;

Lee, So Jeong ;

Jeon, Da Ye .

EJSO, 2023, 49 (02) :392-398

[24] Luminal (Her2 negative) prognostic index and survival of breast cancer patients [J].

Chen, Xuesong ;

Cong, Yingying ;

Pan, Lihua ;

Jiang, Ying ;

Meng, Qingwei ;

Sun, Lichun ;

Pang, Hui ;

Zhao, Yanbin ;

Dong, Xiaoqun ;

Cai, Li .

CANCER EPIDEMIOLOGY, 2014, 38 (03) :286-290

[25] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer [J].

Zhao, Jing ;

Krishnamurti, Uma ;

Zhang, Chao ;

Meisel, Jane ;

Wei, Zhimin ;

Suo, Aili ;

Aneja, Ritu ;

Li, Zaibo ;

Li, Xiaoxian .

PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)

[26] Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer [J].

Zhong, Wenjing ;

Yang, Yaping ;

Zhang, Ailing ;

Lin, Wanyi ;

Liang, Gehao ;

Ling, Yun ;

Zhong, Jiajie ;

Yong, Juanjuan ;

Liu, Zihao ;

Tian, Zhenluan ;

Lin, Qun ;

Luo, Qing ;

Li, Yangyang ;

Gong, Chang .

BREAST CANCER, 2020, 27 (06) :1147-1157

[27] Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer [J].

Li, Xin ;

Xu, Yuxiu ;

Ding, Yun ;

Li, Changfei ;

Zhao, Hong ;

Wang, Jiandong ;

Meng, Songdong .

MOLECULAR CANCER, 2018, 17

[28] Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience [J].

Turkel, Alper ;

Dogan, Mutlu ;

Sertesen, Elif ;

Karacin, Cengiz ;

Irkkan, Sultan cigdem ;

Ates, Ozturk .

WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) :340-346

[29] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer [J].

Lauterlein, Jens-Jacob L. ;

Petersen, Eva R. B. ;

Olsen, Dorte Aa ;

Ostergaard, Birthe ;

Brandslund, Ivan .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) :877-883

[30] Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab [J].

Duchnowska, Renata ;

Sperinde, Jeff ;

Czartoryska-Arlukowicz, Bogumila ;

Mysliwiec, Paulina ;

Winslow, John ;

Radecka, Barbara ;

Petropoulos, Christos ;

Demlova, Regina ;

Orlikowska, Marlena ;

Kowalczyk, Anna ;

Lang, Istvan ;

Ziolkowska, Barbara ;

Debska-Szmich, Sylwia ;

Merdalska, Monika ;

Grela-Wojewoda, Aleksandra ;

Zawrocki, Anton ;

Biernat, Wojciech ;

Huang, Weidong ;

Jassem, Jacek .

ONCOTARGET, 2017, 8 (61) :104149-104159

← 1 2 3 4 5 →